<DOC>
	<DOC>NCT03045029</DOC>
	<brief_summary>This is a prospective, observational, multicenter, patient registry to observe and assess the real-world use and tolerability of Orenitram (treprostinil). Patients who are newly initiated on Orenitram for the treatment of pulmonary arterial hypertension (PAH) or who transition from another prostacyclin therapy will be evaluated for 52 weeks to observe dosing regimens, titration schedules, prostacyclin-related adverse events (AEs), and clinical outcomes of interest.</brief_summary>
	<brief_title>ADAPT - A Patient Registry of the Real-world Use of OrenitramÂ®</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Treprostinil</mesh_term>
	<criteria>1. The patient is newly prescribed on Orenitram, per the package insert indication, and plans to initiate therapy with this medication, or has been receiving Orenitram for 21 or fewer days. 2. The patient agrees to dosing, prostacyclinrelated AE of interest record keeping, survey participation during designated time periods, and recording any medication changes and use for the duration of the study. 3. The patient has the ability to answer surveys, use the diary in English, and has access to the internet. 1. The patient has previously received Orenitram for more than 21 days. 2. The patient is currently receiving epoprostenol therapy or has received epoprostenol within 30 days of enrollment (except if received during acute vasodilator testing). 3. The patient is currently participating in an investigational drug or device study within 30 days of enrollment. Coenrollment in other noninterventional studies is allowed.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>PAH</keyword>
	<keyword>Oral Treprostiinil</keyword>
	<keyword>Orenitram</keyword>
</DOC>